



FIG. 1b




FIG. 1a




FIG.1d




FIG.1c

3/17




FIG. 2a

FIG. 2b

FIG. 2c




FIG. 2d

FIG. 2e

5/17




FIG. 3

6/17




FIG. 4

7/17





FIG. 5





9/17

- E:T RATIO 60
- E:T RATIO 30
- ▨ E:T RATIO 15
- ▩ E:T RATIO 7.5

L1210 TARGETS (T)




FIG. 6B

10/17




FIG. 7

11/17




FIG. 8a







FIG. 8b

12/17




FIG. 10


## Insulin + hybridoma




## allo MLR Proliferation




## allo MLR IL-2




## allo MLR +/- anti B7



15/17






- A**
- ▲ L1210/P815 (7X)
  - ▼ L1210/HY38/GM-CSF (7X)
  - ◆ P815/P815 (7X)
  - P815/HY38/GM-CSF (3X)
  - P815/HY38/GM-CSF (7X)
- B**
- ▼ untreated mice + P815 ascite
  - surviving mice treated with HY38/GM-CSF (7X) + P815 ascite
  - surviving mice treated with HY38/GM-CSF (3X) + P815 ascite







17/17



## Proliferation of lymph node cells (Thymidin uptak )



## Interleukin 2 secretion



## Interferon gamma secretion

